Brief: Orexo Announces Positive Pre-Clinical Data For Nasal Atipamezole Using Amorphox Technology
19/05/2026 07:05
May 19 (Reuters) - Orexo AB ORX.ST: ANNOUNCES POSITIVE PRE-CLINICAL DATA FOR NASAL ATIPAMEZOLE USING AMORPHOX TECHNOLOGY STUDY SHOWS RAPID INTRANASAL ABSORPTION OF ATIPAMEZOLE, ESTABLISHES PROOF-OF-CONCEPT NEXT MILESTONE IS TYPE C FDA MEETING TO ENABLE HUMAN CLINICAL TRIALS Source text: ID:nMFN6Qwg4j Further company coverage: ORX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;))
Recent news on Orexo AB
See all newsBrief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Outcome From An In-Vivo Study Of Ox390
Brief: Orexo Announces Positive Pre-Clinical Data For Nasal Atipamezole Using Amorphox Technology
Brief: Orexo AB Reports Q1 2026 Net Revenue Of Sek 5.0 Million
Sweden's Orexo Q1 revenue drops, net loss widens